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To determine the role of mutant SOD1 gene (SOD1G93A ) on muscle cell differentiation, we derived C2C12 muscle cell lines carrying
a stably transfected SOD1G93A gene under the control of a myosin light chain (MLC) promoter-enhancer cassette. Expression of
MLC/SOD1G93A in C2C12 cells resulted in dramatic inhibition of myoblast differentiation. Transfected SOD1G93A gene expression in
postmitotic skeletal myocytes downregulated the expression of relevant markers of committed and differentiated myoblasts such as
MyoD, Myogenin, MRF4, and the muscle specific miRNA expression. The inhibitory effects of SOD1G93A gene on myogenic program
perturbed Akt/p70 and MAPK signaling pathways which promote differentiation cascade. Of note, the inhibition of the myogenic
program, by transfected SOD1G93A gene expression, impinged also the identity of myogenic cells. Expression of MLC/SOD1G93A in
C2C12 myogenic cells promoted a fibro-adipogenic progenitors (FAPs) phenotype, upregulating HDAC4 protein and preventing
the myogenic commitment complex BAF60C-SWI/SNF. We thus identified potential molecular mediators of the inhibitory effects
of SOD1G93A on myogenic program and disclosed potential signaling, activated by SOD1G93A , that affect the identity of the myogenic
cell population.

1. Introduction
The function of the metalloenzyme SOD1 is to convert
superoxide, a toxic by-product of mitochondrial oxidative
phosphorylation, to water or hydrogen peroxide. However,
alteration in wild type SOD1 expression or mutations in
the gene have been held responsible for the activation of
catabolic pathways associated with degenerative diseases,
including amyotrophic lateral sclerosis (ALS) [1]. ALS is
a disorder involving the degeneration of motor neurons,
muscle atrophy, and paralysis [1]. In few familiar forms of
ALS, mutations in SOD1 gene have been associated with
the pathogenesis of the disease [1]. Initially it has been
suggested that mutation in SOD1 gene led to a decrease in
the protein enzymatic activity (loss of function hypothesis).
However, subsequent studies have clarified that mutant SOD1
possesses a neurotoxic property (gain of function hypothesis)
responsible for the pathogenic mechanism of the disease [2].

Indeed, the finding that overexpression of mutant SOD1 in
transgenic mice recapitulates several clinical features of ALS
disease even in the presence of endogenous mouse SOD1
has led to the conclusion that the disease results from a
toxic gain of function [3]. Mutations in SOD1 that impair its
functions may lead to increased oxidative damage, promoting
the activation of apoptotic pathways.
Oxidative stress plays an important role in the physiopathology of tissues. The effects of the reaction oxidative
species (ROS) are dose-dependent, and low ROS concentration is necessary to guarantee cellular homeostasis while
high ROS dose exerts toxic effects on the cells and may
contribute to cellular dysfunction. Indeed, oxidative stress
is a hallmark of aging and several chronic diseases such as
Alzheimer’s disease, Duchenne dystrophy, and ALS [4]. How
such an oxidative insult plays a direct role in the diseaserelated decrease of muscle performance and mass remains
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largely unknown. In addition, the discrepancy among different studies has further complicated the achievement of a
conclusive link between altered balance of ROS generation
and altered homeostasis-associated diseases.
In a previous work we demonstrated that muscle specific
expression of the mutant isoform of SOD1 gene (SOD1G93A )
induces muscle atrophy associated with a significant reduction in muscle strength and alterations in the contractile
apparatus [5]. We provided evidences that muscle-restricted
expression of SOD1G93A gene is sufficient to increase oxidative stress and to induce a reduction in protein synthesis and
the activation of proteolytic pathway [6].
It has been demonstrated that lactate-induced oxidative
stress delays C2C12 differentiation [7] while treatment of the
same cell line with resveratrol, that confers resistance against
oxidative stress, promotes myogenesis and hypertrophy [8].
Interestingly, high glucose-induced oxidative stress has been
correlated with lipid deposition in muscle derived stem cells
leading to their adipogenic differentiation [9].
In this study, we address the role of the toxic effect of
mutant SOD1 gene (SOD1G93A ) on in vitro myogenic program and we demonstrate that SOD1G93A expression prevents myoblasts differentiation and retains C2C12 cells in
an undifferentiated state that show features common to
fibro/adipogenic cells.

2. Materials and Methods
2.1. Generation of C2C12 MLC/SOD1G93A . C2C12 cells were
stably transfected with pPURO and pMexMLC/SOD1G93A
plasmids (ratio 1 : 10) by using SuperFect Transfection
Reagent (Qiagen) according to the manufacturer’s instructions, as control C2C12 cells were also transfected with
pPURO and pMex empty vector. After 1 day from transfection
the medium was replaced with fresh medium containing
puromycin 3 𝜇g/mL (Sigma Aldrich). After 48 hours the cells
were split 1 : 10 into the selective medium. The medium was
changed every 2 days for 8 days. Single clones were picked,
plated in 60 mm dishes, and expanded.
2.2. Cell Culture. C2C12 and C2C12 MLC/SOD1G93A cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) with 4.5 g/L glucose, L-glutamine (Sigma), supplemented with 15% fetal bovine serum (Gibco), 100 U/mL
penicillin (Sigma Aldrich), 100 𝜇g/mL streptomycin (Sigma
Aldrich), and 2,5 𝜇g/mL of puromycin (Sigma Aldrich) for
C2C12 MLC/SOD1G93A cells. To induce differentiation, cells
were shifted to differentiation medium (DM), DMEM with
2% horse serum (Gibco). Cells were harvested at D0, D2 (48 h
after shift in DM), and D5 (120 h after shift in DM).
2.3. Protein Extraction and Western Blot Analysis. C2C12
and C2C12 MLC/SOD1G93A cells grown in 60 mm culture
dishes were washed twice with cold phosphate-buffered saline, pelleted, resuspended in 100 uL of modified lysis
buffer (Tris-HCl, ph 7.5/20 mM, EDTA/2 mM, EGTA/2 mM,
sucrose/250 mM, DTT/5 mM, Triton-X/0.1%, PMSF/1 mM,
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NaF/10 mM, SOV4/0.2 mM, and cocktail protease inhibitors/
1X (Sigma Aldrich)), and processed for western blot analysis.
Filters were blotted with antibodies against hSOD1 (Santa
Cruz), gp91phox (BD) anti-Perilipin 2 (Lifespan Biosciences),
phospho-p42/p44 MAPK (Millipore), p42/p44 MAPK (Cell
Signaling) phospho-Akt (Thr 308) (Sigma Aldrich), Akt (Cell
Signaling), phospho-P70 (Thr389) (Cell Signaling), p70 (Cell
Signaling), and HDAC4 (Cell Signaling). Protein levels of 𝛼tubulin were used as control for equal protein loading. Signals
were acquired by ChemiDoc-It Imaging System (UVP, LLC)
and the analysis was performed using VisionWorks LS Image
Acquisition analysis software.
2.4. RNA Extraction and Quantitative RT-PCR. Total RNA
extraction was performed using TRIzol reagent method
(Sigma Aldrich) as described by the manufacturers. MicroRNA (miRNA) was reverse-transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies), and mRNA was reverse-transcribed using QuantiTect Reverse Transcription Kit (Qiagen). The reversetranscription reactions were performed according to the
manufacturers’ instructions. Quantitative PCR was performed on an ABI PRISM 7500 SDS (Life Technologies),
using premade 6-carboxyfluorescein- (FAM-) labeled TaqMan assays for beta actin, Pax7, Pax3 MyoD, Myogenin,
MRF4, and Smarcd3 (Life Technologies). FAM-labeled TaqMan MicroRNA Assays for miR1, miR133a, miR206, and
U6 snRNA (Applied Biosystems, USA) were performed as
described. Quantitative RT-PCR sample values were normalized to the expression of beta-actin or U6 snRNA for mRNA
and microRNA, respectively. The relative level for each gene
and miRNA was calculated using the 2-DDCt method [10]
and reported as mean fold change in gene expression.
2.5. Lipid Staining. Lipid accumulation was visualized by Oil
Red O staining. Cells were fixed in 4% paraformaldehyde
for 1 h. After being washed with ddH2O, cells were treated
with 100% propylene glycol for 5 min and stained with a
filtered Oil Red O solution (0.5% Oil Red O in propylene
glycol) for 8 min at 60∘ C. The cells were treated with 85%
propylene glycol solution for 5 min, washed twice with
ddH2O, and mounted with glycerol. All reagents for this
staining were from Sigma Aldrich. Samples were visualized
using an inverted microscope (Axioskop 2 plus; Carl Zeiss
MicroImaging Inc.).
2.6. Trichostatin Treatment. C2C12 and C2C12 MLC/
SOD1G93A cells were exposed to 100 nm (Sigma Aldrich)
Trichostatin A (TSA) in GM (growth medium) for 24 h.
TSA was removed and the cells were analyzed for myosin
expression (at day 5 in DM) or by cytofluorimetric profile (at
day 2 in DM).
2.7. Morphometric Analysis. Cells were fixed in 4%
paraformaldehyde and incubated overnight at 4∘ C with
primary antibody against MHC (MF-20 Hybridoma Bank);
nuclei were visualized using Hoechst staining. Samples were
viewed under an inverted microscope (Axioskop 2 plus; Carl
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Zeiss MicroImaging Inc.). To quantify the differentiation
and fusion of control and TSA treated we calculated the
differentiation index as the percentage of MHC-positive
cells above total nuclei and the fusion index as the average
number of nuclei in MHC-positive cells with at least three
nuclei above total number of nuclei, respectively. The images
were analyzed using ImageJ software.

MLC-1 promoter
1500 bp

SOD1G93A
500 bp

SV40-polyA
800 bp

MLC1-enhancer
920 bp

(a)
G93A

−

SOD1

+

−

+

hSOD1
𝛼-Tubulin

G93A

2.9. Statistical Analysis. Statistical analysis was performed
with GraphPad Prism Software. All data are expressed as
mean ± SEM. Groups were compared using nonparametric
tests (Mann Whitney Rank Sum test) and Student’s t-test. A
𝑃 value of <0.05 was considered statistically significant.

3. Results
3.1. Muscle Specific Expression of Mutant SOD1 Gene Prevents
Differentiation of C2C12 Cells. To investigate the role of
mutant SOD1G93A gene in myoblast differentiation we stably
transfected the C2C12 cells line with the MLC/SOD1G93A
expression cassette (Figure 1(a)) that allows the expression
of the mutated isoform of SOD1 gene under the control
of the myosin light chain promoter [11]. As expected,
SOD1G93A transgene expression was accumulated in C2C12
MLC/SOD1G93A cells induced to differentiate (Figure 1(b)).
The postmitotic expression of SOD1G93A transgene induced
the accumulation of Gp91 protein, a marker of mitochondria
oxidative damage (Figure 1(c)) that might mediate the toxic
properties of mutant SOD1 on muscle differentiation and
homeostasis. To explore if SOD1G93A transgene expression
directly interferes with muscle differentiation, we stimulated
differentiation by shifting the cells from growth to the differentiation medium (DM) (Figure 2(a)). Morphological and
immunofluorescence analysis revealed a dramatic inhibition
of muscle differentiation in C2C12 MLC/SOD1G93A cells, with
significant reduction in the number and size of the myosin
positive cells, compared with control C2C12 myotubes (Figures 2(a)-2(b)). Morphometric analysis revealed a complete
inhibition of fusion index, quantified as the percentage of
Hoechst-stained nuclei located within multinucleated cells,
positive to sarcomeric myosin (Figure 2(b)). The altered
differentiated muscle phenotype was also confirmed by western blot analysis, revealing a drastic downmodulation of
the sarcomeric myosin heavy chain expression, a specific
marker of myogenic differentiation (Figure 2(c)). Of note,
C2C12 cells stably transfected with wild type SOD1 cassette
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2.8. Flow Cytometry. C2C12 and C2C12 MLC/SOD1
were detached from culture with 0.25% trypsin, 2 mM EDTA
(Sigma Aldrich) at indicated times. The isolated cells were
then filtered through a 40 𝜇m cell strainer (Falcon) and incubated with the following antibodies (10 ng/mL): CD31-PECy7,
CD45-eFluor 450 (eBioscience), Sca-1-FITC (Macs), and 𝛼7
integrin-PE (R&D Systems Inc.). A subsequent incubation
with 7-aminoactinomycin D (1/1000; Sigma) was performed
to stain nonviable cells. For each analysis, data were collected
from 10,000 cells and analyzed on CyAN ADP (Dako) flow
cytometer using the Summit 4.3 software (Dako).
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0.0
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(c)

Figure 1: Characterization of C2C12 MLC/SOD1G93A . (a) Schematic
representation of MLC/SOD1G93A construct. (b) Western blot analysis for mutant human SOD1G93A protein in C2C12 and C2C12
MLC/SOD1G93A at different time points during differentiation. (c)
Upper panel shows representative western blot analysis of gp91phox
expression in C2C12 and C2C12 MLC/SOD1G93A cells. Lower panel
shows the relative densitometric analysis of C2C12 (white bars)
and C2C12 MLC/SOD1G93A (black bars). D2 and D5 referred to
days of culture in differentiation condition. Data are represented as
mean ± SEM.

(MLC/SOD1Wt ) did not show any morphological differences
compared to control C2C12 cell lines (data not shown).
A key myogenic factor that triggers myoblast differentiation is MyoD [12, 13], which resulted in significant
downregulation throughout the time course of differentiation
in C2C12 MLC/SOD1G93A cells (Figure 3(a)). Myogenin is
the myogenic factor that functions downstream of MyoD
and plays a critical role in triggering terminal differentiation
process of myoblasts [12, 14]. Myogenin expression resulted
in significant downregulation in C2C12 MLC/SOD1G93A
cells during differentiation (Figure 3(b)). The final stage of
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Figure 2: Postmitotic expression of mutant SOD1 gene inhibits C2C12 cells differentiation. (a) Representative immunofluorescence images of
C2C12 and C2C12 MLC/SOD1G93A cells stained with anti-myosin heavy chain (MHC) antibody after 5 days in differentiation medium. (b) The
histograms represent the differentiation index (left panel) and fusion index (right panel) in control (white bars) and transfected cells (black
bars). (c) Upper panel shows representative western blot analysis of MHC expression in C2C12 and C2C12 MLC/SOD1G93A cells. Lower panel
shows densitometric analysis for MHC expression in C2C12 (white bars) and C2C12 MLC/SOD1G93A (black bars). D0, D2, and D5 referred
to days of culture in differentiation condition. Data are represented as mean ± SEM (∗ 𝑃 < 0.05).
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Figure 3: Mutant SOD1 gene downmodulates the players involved in C2C12 differentiation. Real time PCR for MyoD (a), Myogenin (b),
MRF4 (c), miR133a (d), miR206 (e), and miR1 (f) in both control (white bars) and transfected cells (black bars). D0, D2, and D5 referred to
days of culture in differentiation condition. Data are represented as mean ± SEM (∗ 𝑃 < 0.05; ∗∗ 𝑃 < 0.005).

skeletal muscle differentiation and maturation program is
also dependent on the concerted action of another myogenic
factors, namely, MRF4, which promotes the activation of
myosin heavy chain expression [12]. Real time PCR analysis
revealed a significant reduction of MRF4 transcripts in C2C12
MLC/SOD1G93A cells during differentiation, compared to
control C2C12 myotubes (Figure 3(c)).
Recent works have shown that among genes which are
important for proper muscle differentiation and function,
microRNAs (miRNAs) play a crucial role [15–17]. Among
them miR133, miR206, and miR1 are abundantly expressed
in muscle tissue and specifically induced during myogenesis
and C2C12 differentiation [18]. It has been reported that
miR1 and miR133 are involved in a complex molecular

mechanism by which miR1 induces the downmodulation
of an inhibitor of muscle differentiation, namely, histone
deacetylase (HDAC) 4 [19] and miR133, which is clustered on
the same chromosomal loci of miR1 and enhances myoblast
proliferation inhibiting the serum response factor (SRF).
In addition, miR206 facilitates satellite cell differentiation
[20, 21] by restricting its proliferative potential through the
repression of Pax-7 expression [22]. These findings implicate
these myomiRNAs in a complex regulatory loop to control
cell proliferation, commitment, and differentiation. Real
time PCR analysis revealed a significant downmodulation of
miR133, miR206, and miR1 during the differentiation time
course of C2C12 MLC/SOD1G93A cells compared to control
C2C12 cells (Figures 3(d), 3(e), and 3(f)).
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3.2. Muscle Specific Expression of Mutant SOD1 Gene Perturbs
Signaling Pathways of Muscle Differentiation. The activation
of a specific developmental program requires the integration
of multiple extrinsic signals from the cell membrane that
culminate in changes of nuclear gene expression patterns.
Among the known signal transduction intermediates in muscle cells, the serine/threonine kinase AKT and the mitogenactivated protein kinases (MAPK) have been shown to
modulate myogenic differentiation [23]. In a previous study
[6], we have demonstrated that muscle specific expression of
SOD1G93A gene in transgenic animals promotes a reduction
of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and
leads to muscle atrophy.
In this study, we explored whether the inhibitory effects
of mutant SOD1 gene on myogenic program perturb the relevant signaling pathways of the myogenic program. Figure 4
shows that the absolute ratio of pAkt/Akt was negatively regulated (Figure 4(a)) and pP70/P70, the downstream effector
of AKT, was significantly reduced in C2C12 MLC/SOD1G93A
cultures compared with control C2C12 cells (Figure 4(b)). In
addition we observed a significant downmodulation of the
phosphorylated active form of a factor associated with MAPK
differentiation cascade, namely, ERK1/2 (Figure 4(c)).
Overall these results demonstrate that the postmitotic
expression of SOD1 mutant gene prevents C2C12 differentiation, affecting the activation of the muscle regulatory
factors, muscle miRNA, and the signal transduction cascades
responsible for myogenic differentiation, and might impinge
the maintenance of the muscle phenotype.
3.3. Muscle Specific Expression of SOD1G93A Impinges the Identity of Muscle Cells and Promotes a FAPs Phenotype in C2C12
Myogenic Cells. To validate this hypothesis, we analyzed the
expression of Pax-7, which is a key factor that triggers the
specification of uncommitted skeletal muscle progenitors
to myogenic cells [24]. Of note, we observed a complete
inhibition of Pax-7 expression in C2C12 MLC/SOD1G93A cells
compared to C2C12 myoblasts, suggesting that SOD1G93A
expression not only inhibits muscle differentiation but also
confers to transfected cells an immature state (Figure 5(a)).
Recently, it has been demonstrated that satellite cells in
adult muscle are bipotential stem cells that can give rise
to brown adipogenic as well as myogenic progenitors [25].
The lineage switch between myogenic and brown adipogenic
commitment is controlled by the muscle specific miR133a,
which is highly expressed in satellite cells and can repress
the expression of adipogenic markers to enforce myogenic
commitment in satellite cells [25].
Further, recent evidences revealed that Pax-3 transcription factor, whose ectopic expression in C2C12 myoblasts
efficiently inhibits myogenic specification [26], plays a pivotal
role during differentiation into adipocytes cells of humaninduced pluripotent stem cells [27]. In addition, the exclusive
expression of Pax-3 or MyoD gene in stem cells allows a clear
and distinct choice between myogenic and fibro/adipogenic
potential cell lineage [28]. Based on these evidences, we
performed real time PCR and histochemical analysis in
both C2C12 and C2C12 MLC/SOD1G93A cells to evaluate
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the potential adipogenic features in C2C12 MLC/SOD1G93A
transfected cell lines. As shown in Figure 5(b) the levels of Pax-3 transcript were significantly upregulated in
C2C12 MLC/SOD1G93A during all stages in culture, compared to C2C12. Moreover Oil Red O staining revealed
the accumulation of intracellular lipid droplets in C2C12
MLC/SOD1G93A cells (Figure 5(c)). These data were corroborated by western blot analysis for Perilipin 2 (Plin2),
a marker of fatty acids uptake and storage [29]. Western
blot analysis revealed that Plin2 protein was accumulated
in C2C12 MLC/SOD1G93A during the differentiation process
compared to control cell line (Figure 5(d)). All these results
together with the data of miR133a and MRFs downmodulation in C2C12 MLC/SOD1G93A (Figure 3) suggest that muscle
specific expression of SOD1 mutant gene inhibits myoblasts
differentiation and promotes adipogenic features in C2C12
cells through a miR133a and Pax-3 dependent mechanism.
Fibro-adipogenic progenitors (FAPs) are multipotent
mesenchymal cells residing in skeletal muscle interstitium
[30–32]. These cells are negative for CD31, CD45, and
𝛼7 integrin surface antigens and are characterized by the
expression of the stem cell antigen 1 (Sca1) [30]. FAPs convert
environmental cues into signals that modulate muscle regeneration or turn themselves into fibro-adipocytes, inducing fat
deposition and fibrosis under pathologic conditions, such as
dystrophic muscles [33].
To verify whether postmitotic expression of SOD1 mutant
gene promotes a FAPs phenotype in C2C12 cells, we performed FACS analysis (Figure 6(a)) for Sca1, CD31, CD45,
and 𝛼7 integrin. C2C12 and C2C12 MLC/SOD1G93A cells
were negative for CD31 and CD45 antigens (data not shown).
C2C12 were mainly 𝛼7 integrin+ and a low percentage of
them was Sca1+ and 𝛼7 integrin− (Figures 6(a)–6(c)). In
contrast, C2C12 MLC/SOD1G93A were mainly Sca1+ and 𝛼7
integrin− , with a significant reduction in the number of
𝛼7 integrin+ cells (Figures 6(a)–6(c)). These results clearly
evidenced the presence of fibro/adipogenic features in C2C12
MLC/SOD1G93A . The molecular mechanism that, in concert
with environmental cues, controls the identity and activity of
FAP cells involves a HDAC-regulated network; this network
consists of muscle specific miRNAs that target two alternative
variants of the SWI/SNF chromatin remodeling complex,
BAF60A and BAF60B, and favor the formation of a BAF60Cbased SWI/SNF complex able to confer on MYOD the ability
to activate the myogenic program [34].
We analyzed the protein and transcript levels, respectively, of HDAC4 and BAF60C in both C2C12 and C2C12
MLC/SOD1G93A cells. We observed that HDAC4 was significantly upregulated in cultures of C2C12 MLC/SOD1G93A
cells compared to control differentiated (day 5 in DM) C2C12
cells (Figure 7(a)). In contrast, BAF60C was significantly
downregulated in C2C12 MLC/SOD1G93A cells (Figure 7(b)).
To better correlate the induction of FAPs phenotype
and HDAC activity with SOD1G93A expression and toxic
properties, we treated C2C12 MLC/SOD1G93A cells with the
HDAC class II inhibitor Trichostatin (TSA) and analyzed
the signature profile of both FAPs and myogenic cells.

Mediators of Inflammation
SOD1G93A

7

−

−

+

−

+

+

pAkt Thr 308

SOD1G93A
pP70 Thr 389

Total Akt

Total P70

𝛼-Tubulin

−

−

+

+

−

+

𝛼-Tubulin
D0

D2

D5

D0

2.5

D2

D5

4
∗

2.0
a.u. relative to calibrator

a.u. relative to calibrator

3
1.5

1.0

2

1

0.5

0.0

0
D0

D2

D0

D5

(a)
SOD1G93A
pP42/44 MAPK

−

+

−

+

D2

D5

(b)
+

−

Total P42/44 MAPK
𝛼-Tubulin
D0

D2

D5

1.5

a.u. relative to calibrator

∗

1.0

0.5

0.0
D0

D2

D5

(c)

Figure 4: Muscle specific expression of human mutant SOD1 gene alters signaling pathways in muscle differentiation. (a) Representative
western blot analysis for phospho-Akt (Thr 308) and total Akt expression (upper panel) and densitometric analysis (lower panel) of the
ratio between phosphorylated Akt and the total form (lower panel) in C2C12 (white bars) and C2C12 MLC/SOD1G93A (black bars). (b)
Representative western blot analysis for phospho-P70 (Thr 389) and total P70 expression (upper panel) and densitometric analysis (lower
panel) of the ratio between phospho-P70 and total P70 (lower panel) in C2C12 (white bars) and C2C12 MLC/SOD1G93A (black bars). (c)
Representative western blot analysis of phospho-p42/44 MAPK and p42/44 MAPK expression (upper panel) and densitometric analysis
(lower panel) of the ratio between phospho-p42-44 MAPK and total p42/44 MAPK in C2C12 (white bars) and C2C12 MLC/SOD1G93A (black
bars). D0, D2, and D5 referred to days of culture in differentiation condition. Data are represented as mean ± SEM (∗ 𝑃 < 0.05).
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Figure 5: C2C12 MLC/SOD1G93A cells exhibit adipogenic features. Real time PCR analysis for Pax7 (a) and Pax3 (b). (c) Upper panel shows
Oil Red O staining and phase contrast of control C2C12 and C2C12 MLC/SOD1G93A transfected cells at day 5 in culture. (d) Upper panel
shows representative western blot analysis of Plin2 and relative densitometric analysis (lower panel) of the ratio between Plin2 and 𝛼-tubulin
in C2C12 (white bars) and C2C12 MLC/SOD1G93A (black bars). D0, D2, and D5 referred to days of culture in differentiation condition. Data
are represented as mean ± SEM (∗ 𝑃 < 0.05; ∗∗∗ 𝑃 < 0.0005).

Cytofluorimetric profile revealed that TSA treatment induced
a significant downmodulation of Sca1+ and 𝛼7 integrin−
cells (Figure 7(c)) and an increased percentage of double
positive Sca1+ and 𝛼7 integrin+ cells (Figure 7(d)). Of note
we did not observe any significant difference in the number
of 𝛼7 integrin+ Sca1− cells after treatment (data not shown)
suggesting that TSA treatment is able to counteract the
establishment of a FAP phenotype but it only partially
rescued the muscle phenotype. To support this evidence,

we induced muscle differentiation in C2C12 MLC/SOD1G93A
cells treated with TSA and we revealed that inhibition of
HDAC activity partially rescued myogenic differentiation,
promoting myoblast fusion and differentiation (Figures 7(e)7(f)).
Overall these data suggest that the postmitotic expression
SOD1G93A mutant gene promotes a FAPS phenotype in
C2C12 cells, by upregulating HDAC4 protein and preventing
the BAF60C-SWI/SNF complex myogenic commitment.
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Figure 6: Expression of mutant SOD1 promotes a FAPS phenotype in C2C12 cells. (a) Flow cytometry profile for 𝛼7 integrin and Sca1
expression from control C2C12 and transfected C2C12 MLC/SOD1G93A cells at days 2 and 5 in differentiation medium. (b, c) Histograms
of the percentage of 𝛼7 integrin (b) and Sca1 (c) positive cells of C2C12 (white bars) and C2C12 MLC/SOD1G93A (black bars) cells. D2 and D5
referred to days of culture in differentiation condition. Data are represented as mean ± SEM (∗ 𝑃 < 0.05; ∗∗∗ 𝑃 < 0.0005).
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Figure 7: The acquisition of fibro-adipogenic features involves a HDAC-regulated network. (a) Upper panel shows western blot analysis of
HDAC4 expression in C2C12 and C2C12 MLC/SOD1G93A cells and densitometric analysis (lower panel) of the ratio between HDAC4 and
𝛼-tubulin. (b) Real time PCR for BAF60C in C2C12 (white bars) and C2C12 MLC/SOD1G93A (black bars). (c, d) Histograms of the percentage
of Sca1 (c) and positive 𝛼7 integrin cells (d) of control C2C12 MLC/SOD1G93A (black bars) cells and TSA treated C2C12 MLC/SOD1G93A
cells (grey bars). D2 referred to days of culture in differentiation condition. (e) Representative immunofluorescence analysis for MHC after
5 days in differentiation medium in untreated (left panel) and TSA treated (right panel) C2C12 MLC/SOD1G93A cells. (f) Histograms of the
differentiation index (left panel) and fusion index (right panel) in control (black bars) and treated cells (grey bars). D2 and D5 referred to
days of culture in differentiation condition. Data are represented as mean ± SEM (∗ 𝑃 < 0.05; ∗∗ 𝑃 < 0.005).

4. Discussion
In this work we defined the specific toxic effects of postmitotic
expression of mutant SOD1G93A gene on the myogenic
program, demonstrating that mutant SOD1G93A alters the
identity of muscle cells, affects cell homeostasis, and inhibits
muscle differentiation.
The physiological activity of the metalloenzyme SOD1 is
to detoxify the cells from the accumulation of free radicals,
converting superoxide, a toxic by-product of mitochondrial
oxidative phosphorylation, to water or hydrogen peroxide.
In contrast, the mutant SOD1 possesses a toxic property
that is responsible for the pathogenic mechanism of ALS, a
neurodegenerative disease associated with the degeneration
of motor neurons, muscle atrophy, and paralysis.
Different studies also support the evidence that skeletal
muscle is a primary target of mutant SOD1 toxicity in mice [5,
35], indicating that dysfunctions of affected muscle cells are
not only a marginal consequence of denervation associated
with motor neurons loss, but a direct consequence of cell
muscle toxicity of mutant SOD1 [36]. The understanding of
the mechanisms involved in mutant SOD1 toxicity in muscle
may facilitate the design of treatments directed toward this
specific tissue to treat ALS or at least to delay disease
progression.
The aim of our work was to define the responses of
myogenic cells to the toxic effects of SOD1G93A and the
signaling pathways that mediated the toxic properties of
mutant SOD1 product. To this purpose, we generated a
stable transfected C2C12 cell line, overexpressing the mutated

isoform of the SOD1 gene under the control of the MLC
promoter [11, 37].
Postmitotic expression of SOD1G93A gene induced an
excess of oxidative stress, as evidenced by the increased
expression of gp91 protein, and impaired muscle differentiation and fusion of C2C12 cells, inducing a significant
downregulation in the expression of molecular markers of
myogenic differentiation, like MyoD, Myogenin, MRF4, and
sarcomeric myosin heavy chain.
Epigenetic factors, including miRNAs expression, play
important role in muscle homeostasis and represent good
molecular markers to define the stage of myogenic program
and to monitor the effects of toxic factors on the modulation
of muscle phenotype. miR206, miR133a, and miR1 [18, 20,
38] contribute to the proper development of the myogenic
program, and their alteration can impair the myogenic
differentiation. Based on this evidence, we investigated their
expression levels in C2C12 MLC/SOD1G93A cells and demonstrated that transfected MLC/SOD1G93A induced a significant
downmodulation of all muscle microRNAs analyzed.
The myogenic program is governed by specific pathways
of signal transduction. Here we have demonstrated that the
inhibitory effect of the toxic SOD1G93A protein on myogenic
differentiation acts negatively on two major signaling pathways involved in muscle differentiation, such as the AKT/p70
and MAPK pathways.
These results suggest that muscle expression of SOD1G93A
impinges muscle differentiation and might alter the identity
of muscle cells in line with previous studies that demonstrate
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the impairment of myofiber-associated skeletal muscle satellite cells function in SOD1-G93A mice [39] and the altered
expression of myogenic regulatory factors in the mouse
model of amyotrophic lateral sclerosis [40].
Recent evidences indicate that ROS levels correlate with
a high concentration of glucose. Aguiari and colleagues [9]
have shown that high glucose growth medium induces an
increase in ROS production and promotes the adipocyte
differentiation of muscle derived stem cells [9].
Since C2C12 MLC/SOD1G93A cells show higher levels
of oxidative stress and impaired myogenic differentiation
process, modulating relevant genes and myomiRNA of the
maintenance of the muscle phenotype, we supposed a link
between toxic properties of SOD1G93A and activation of
adipogenic differentiation. In particular, we demonstrated
that transfected MLC/SOD1G93A cells show low levels of
miR133a, Pax-7, and MyoD expression and high levels of Pax3 and Perilipin 2, a marker of lipid droplets.
Our data support the evidences by Yin and colleagues [25]
who showed that miR133a controls satellite cells commitment
to the adipocyte lineage; in this work the authors demonstrated that miR133a inhibition promotes proadipogenic
differentiation of satellite cells and that the new-formed
preadipocytes completely lose the expression of both Pax7 and MyoD [41]. Moreover, Mohsen-Kanson et al. [27]
demonstrated that Pax-3 plays a pivotal role during stem
cell differentiation into adipocytes and that the exclusive
expression of Pax-3 or MyoD allows cells to choose between
myogenic and fibro/adipogenic cell lineage.
Our data indicate that muscle expression of SOD1G93A
induced deregulation of myogenic process, led to the impairment of myoblast differentiation, and promoted adipogenic
commitment.
The fibro-adipogenic precursors or FAPs cells are bipotent cells positive for Sca1 and negative for 𝛼7 integrin, CD31,
and CD45, markers of satellite cells, endothelial cells, and
hematopoietic cells, respectively. FAPs are mesenchymal cells
residing in skeletal muscle interstitium and quiescent in physiological conditions and are efficiently activated to proliferate
after muscle injury [30]. FAPs convert environmental factors
into specific signals that can modulate muscle regeneration
[34]. It has been shown that FAPs may exacerbate the dystrophic phenotype turning into fibro-adipocytes, mediating
fat deposition and fibrosis [33] and thereby disrupting the
environment conducive for muscle regeneration.
The trigger that controls FAP lineage commitment and
activity is currently unknown.
Interestingly, it has been demonstrated that, during
ischemia-induced regeneration, oxidative stress negatively
modulates myogenic differentiation [42] and it is well known
that oxidative stress is a hallmark of chronic disease including
the Duchenne muscle dystrophy where FAPs have been
deeply studied.
Here we demonstrate, by histochemical assay and
FACS analysis, the presence of lipid droplets in C2C12
MLC/SOD1G93A cells and their significant and exclusive positivity for Sca1, demonstrating that C2C12 MLC/SOD1G93A
cells share common features with FAPs.
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A recent study has revealed a link between HDACs,
myomiRs, and chromatin remodeling that underlies FAPs
commitment to the “promyogenic” phenotype [34]. The
authors demonstrated that the signaling pathway that mediates the transition from myogenic to fibro/adipogenic phenotype requires the action of miR1, miR206, and miR133a,
which favor the incorporation of specific core-protein,
BAF60C, into the chromatin remodeling SWI/SNF complex.
Moreover, the authors also demonstrated that in a murine
model of Duchenne dystrophy treatments with the HDACs
inhibitor (TSA) address FAPs to a proper myogenic fate,
blocking the fibro-adipogenic one [34].
Since HDAC4 regulates FAPs fate and since our transfected cell line shares common features with FAPs, including
higher levels of HDAC4 protein, lower levels of BAF60c,
and deregulation of myomiRNA expression, we hypothesized that HDAC4 is responsible for C2C12 MLC/SOD1G93A
adipogenic choice. To prove our hypothesis we treated
C2C12 MLC/SOD1G93A cells with TSA and interestingly we
observed a partial rescue of the myogenic phenotype. This
suggests that inhibition of HDAC activity interferes with
the establishment of a FAP phenotype and partially rescues
muscle differentiation.

5. Conclusions
Three main conclusions can be drawn from the present work;
the postmitotic expression of SOD1 mutant gene (1) induces
the impairment of the myogenic differentiation process of
C2C12 cells; (2) triggers the myoblast towards an adipogenic
phenotype; (3) promotes FAPs features in C2C12 cells by
epigenetic changes that involve HDACs proteins.
Further studies will clarify the different molecular mechanisms that are modulated by multiple toxic effects of mutant
SOD1 protein in skeletal muscle and whether oxidative stress
can represent a determinant for myoblasts choice toward a
fibro/adipogenic fate.
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[37] A. Musarò and N. Rosenthal, “Maturation of the myogenic
program is induced by postmitotic expression of insulin-like
growth factor I,” Molecular and Cellular Biology, vol. 19, no. 4,
pp. 3115–3124, 1999.
[38] R. Taulli, F. Bersani, V. Foglizzo et al., “The muscle-specific
microRNA miR-206 blocks human rhabdomyosarcoma growth
in xenotransplanted mice by promoting myogenic differentiation,” The Journal of Clinical Investigation, vol. 119, no. 8, pp.
2366–2378, 2009.
[39] R. Manzano, J. M. Toivonen, A. C. Calvo et al., “Altered in vitro
proliferation of mouse SOD1-G93A skeletal muscle satellite
cells,” Neurodegenerative Diseases, vol. 11, no. 3, pp. 153–164,
2013.
[40] R. Manzano, J. M. Toivonen, S. Oliván et al., “Altered expression
of myogenic regulatory factors in the mouse model of amyotrophic lateral sclerosis,” Neurodegenerative Diseases, vol. 8, no.
5, pp. 386–396, 2011.
[41] Y. Liu, I. Chakroun, D. Yang et al., “Six1 regulates MyoD
expression in adult muscle progenitor cells,” PLoS ONE, vol. 8,
no. 6, Article ID e67762, 2013.
[42] G. Zaccagnini, F. Martelli, A. Magenta et al., “p66ShcA and
oxidative stress modulate myogenic differentiation and skeletal
muscle regeneration after hind limb ischemia,” The Journal of
Biological Chemistry, vol. 282, no. 43, pp. 31453–31459, 2007.

Mediators of Inflammation

MEDIATORS
of

INFLAMMATION

The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Gastroenterology
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Hindawi Publishing Corporation
http://www.hindawi.com

Diabetes Research
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

International Journal of

Journal of

Endocrinology

Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com

Disease Markers

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Submit your manuscripts at
http://www.hindawi.com
BioMed
Research International

PPAR Research
Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Journal of

Obesity

Journal of

Ophthalmology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Evidence-Based
Complementary and
Alternative Medicine

Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Oncology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Parkinson’s
Disease

Computational and
Mathematical Methods
in Medicine
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

AIDS

Behavioural
Neurology
Hindawi Publishing Corporation
http://www.hindawi.com

Research and Treatment
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Oxidative Medicine and
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

